CathWorks Appoints Chief Financial Officer

KFAR-SABA, ISRAEL and ALISO VIEJO, CA (March 4, 2019) — CathWorks announced that Mike Feher has joined CathWorks as Vice President of Finance and Chief Financial Officer. His appointment coincides with US commercialization of the CathWorks FFRangio™ System. Mr. Feher will initially focus on the development of financial and operational capabilities, as well as creating value for the organization through the execution of company’s strategy.

Mike joins CathWorks with over 13 years of finance and strategy experience in companies such as Edwards Lifesciences, Volcom and Deloitte. That experience includes deep understanding of investor relationships, strategic planning and financial operations. Mike is a certified public accountant. He earned his B.S. in Accounting, Finance and Economics from Chapman University and his MBA from University of Southern California.

Jim Corbett, CathWorks CEO, said of Mike’s appointment, “I am very excited to have Mike join our leadership team. Mike’s strategic mindset and broad financial acumen will be a significant addition to our team. The CathWorks System represents a tremendous opportunity for interventional cardiologists to improve the quality of care and lower costs in the treatment of multi-vessel coronary artery disease. I am confident in Mike’s ability to lead our finance organization as we continue to work towards achieving our strategic plan.”

Mr. Feher said, “I am excited about joining CathWorks and its dynamic leadership team. We look forward to the US commercialization of the CathWorks FFRangio in the next few weeks and cannot wait to see the impact of this transformational technology on patients, physicians, and health systems.”

The CathWorks FFRangio System quickly and precisely delivers the objective FFR guidance needed to optimize PCI therapy decisions for every patient. It is non-invasive and performed intra-procedurally during coronary angiography without adding additional clinical risk or per-procedure costs. The company received U.S. FDA 510(k) clearance for the CathWorks FFRangio Coronary Vascular Physiologic Simulation Software on December 19, 2018.

Contact CathWorks Today